JP2015500294A - 金属過剰症を治療する経口製剤 - Google Patents

金属過剰症を治療する経口製剤 Download PDF

Info

Publication number
JP2015500294A
JP2015500294A JP2014546115A JP2014546115A JP2015500294A JP 2015500294 A JP2015500294 A JP 2015500294A JP 2014546115 A JP2014546115 A JP 2014546115A JP 2014546115 A JP2014546115 A JP 2014546115A JP 2015500294 A JP2015500294 A JP 2015500294A
Authority
JP
Japan
Prior art keywords
compound
dosage form
solid dosage
formula
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014546115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500294A5 (https=
Inventor
ヒュー ワイ． ジュニア リーンホフ，
ヒュー ワイ． ジュニア リーンホフ，
Original Assignee
フェロキン バイオサイエンシーズ， インコーポレイテッド
フェロキン バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48574916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015500294(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by フェロキン バイオサイエンシーズ， インコーポレイテッド, フェロキン バイオサイエンシーズ， インコーポレイテッド filed Critical フェロキン バイオサイエンシーズ， インコーポレイテッド
Publication of JP2015500294A publication Critical patent/JP2015500294A/ja
Publication of JP2015500294A5 publication Critical patent/JP2015500294A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2014546115A 2011-12-09 2012-12-07 金属過剰症を治療する経口製剤 Pending JP2015500294A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161568914P 2011-12-09 2011-12-09
US201161568890P 2011-12-09 2011-12-09
US61/568,890 2011-12-09
US61/568,914 2011-12-09
PCT/US2012/068432 WO2013086312A1 (en) 2011-12-09 2012-12-07 Oral formulations for treating metal overload

Publications (2)

Publication Number Publication Date
JP2015500294A true JP2015500294A (ja) 2015-01-05
JP2015500294A5 JP2015500294A5 (https=) 2016-01-28

Family

ID=48574916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546115A Pending JP2015500294A (ja) 2011-12-09 2012-12-07 金属過剰症を治療する経口製剤

Country Status (9)

Country Link
US (1) US8993606B2 (https=)
EP (1) EP2787994A4 (https=)
JP (1) JP2015500294A (https=)
AR (1) AR089122A1 (https=)
AU (1) AU2012347595A1 (https=)
BR (1) BR112014013985A2 (https=)
CA (1) CA2857990A1 (https=)
TW (1) TW201338777A (https=)
WO (1) WO2013086312A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3620161A1 (en) 2011-12-16 2020-03-11 University of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
JP2016513652A (ja) 2013-03-15 2016-05-16 フェロキン バイオサイエンシーズ， インコーポレイテッド デスアザデスフェリチオシン類似体の多形形態
AU2014352780A1 (en) * 2013-11-22 2016-06-09 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
KR20170140306A (ko) 2015-04-27 2017-12-20 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도
WO2018104130A1 (en) 2016-12-07 2018-06-14 Lumileds Holding B.V. Flash light emitter with remote communication function
EP3999059A1 (en) * 2019-07-19 2022-05-25 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (tdt)
US20250268878A1 (en) 2021-01-20 2025-08-28 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528037A (ja) * 2008-07-14 2011-11-10 フェロキン・バイオサイエンシーズ・インコーポレイテッド 金属キレート化剤としてのデスアザデスフェリチオシンポリエーテル類似体の新規の塩及び多形体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201910900T4 (tr) 2005-04-04 2019-08-21 Univ Florida Desferritiyokin polieter analogları.
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
WO2008115433A1 (en) 2007-03-15 2008-09-25 University Of Florida Desferrithiocin polyether analogues
EP2459544A4 (en) 2009-07-27 2012-12-05 Ferrokin Biosciences Inc DESDAADESFERROTHIOCIN POLYETHERAL ANALOGUE PROGRUGS USING METAL CHLORIDE
WO2011028255A2 (en) 2009-08-25 2011-03-10 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof
EP2566854A4 (en) 2010-05-04 2013-11-06 Shire Llc DESAZADESFERROTHIOCIN AND DEAZADESFERROTHIOCIN POLYETHER ANALOGS AS METAL CHELATORS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528037A (ja) * 2008-07-14 2011-11-10 フェロキン・バイオサイエンシーズ・インコーポレイテッド 金属キレート化剤としてのデスアザデスフェリチオシンポリエーテル類似体の新規の塩及び多形体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RIENHOFF, HUGH YOUNG ET AL: "A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral", HAEMATOLOGICA, vol. 96, no. 4, JPN7016002959, 20 December 2010 (2010-12-20), pages 521 - 525, ISSN: 0003413575 *

Also Published As

Publication number Publication date
TW201338777A (zh) 2013-10-01
US20130225645A1 (en) 2013-08-29
US8993606B2 (en) 2015-03-31
EP2787994A1 (en) 2014-10-15
CA2857990A1 (en) 2013-06-13
WO2013086312A1 (en) 2013-06-13
BR112014013985A2 (pt) 2017-06-13
AR089122A1 (es) 2014-07-30
AU2012347595A1 (en) 2014-06-26
EP2787994A4 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
JP2015500294A (ja) 金属過剰症を治療する経口製剤
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
JP2021522247A (ja) 肝疾患における好中球エラスターゼ阻害薬の使用
JP2013500342A (ja) 金属キレート化剤としてのデサザデスフェロチオシンポリエーテルアナログのプロドラッグ
JP2013525495A5 (https=)
JP2018509474A (ja) インダン酢酸誘導体を用いる肝疾患の治療方法
JP2019533660A (ja) 急性腎障害を処置する方法
JP2015500294A5 (https=)
US11708338B2 (en) Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
WO2019124411A1 (ja) 維持透析下の二次性副甲状腺機能亢進症の予防または治療用医薬組成物
CA3029948A1 (en) Antidiabetic solid pharmaceutical compositions
HUE028159T2 (en) Acid addition salts of risperidone and pharmaceutical compositions containing them
AU2018202714B2 (en) Treatment of androgen deprivation therapy associated symptoms
WO2019246454A1 (en) Method of treating a condition associated with neurodegeneration using inhibitors of oat3
EP2568982B1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
WO2015101794A1 (en) Pharmaceutical composition
US9512095B2 (en) Polymorph forms of desazadesferrithiocin analogs
US20150299151A1 (en) Polymorph forms of desazadesferrithiocin analogs
US10450328B2 (en) Crystals of thiadiazole derivative DPP-IV inhibitors and uses thereof
HK1262206A1 (en) Use of mgbg for manufacturing a medicament for the treatment or prevention of progressive ms and its progression
HK1124851B (en) Solid forms of (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone oxime
HK1124851A1 (en) Solid forms of (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone oxime

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170427